Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Supplemental Cash Flow Information (Tables)

9 Months Ended

Sep. 30, 2017

The following table represents cash flows used in the Company’s discontinued operations for the nine months ended September 30, 2017 and 2016:

	Nine Months Ended
	September 30,
	2017			2016
Net cash used in operating activities of discontinued operations	$	(2,259	)	$	(1,486	)

Net cash used in investing activities of discontinued operations	$	-		$	-

Supplemental Disclosures of Non Cash Financing Activities
(in thousands)

	Nine Months Ended
	September 30,
	2017			2016

Write-off of the RedPath Note	$	(8,098	)	$	-
Issuance of the Exchange Notes	$	11,375		$	-
Non-cash equity conversion costs	$	(173	)	$	-
Debt issuance costs	$	(511	)	$	-
Warrants issued through Termination Agreement (See Note 14, Equity)	$	193		$	-
Shares issued in debt exchange	$	11,643		$	-
Professional fees paid by a third party	$	685		$	-